DBpedia 2016-04

Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2502747> ?p ?o }

Showing triples 1 to 99 of 99 with 100 triples per page.

Q2502747 subject Q22921233.
Q2502747 subject Q22948482.
Q2502747 subject Q6814466.
Q2502747 subject Q6938881.
Q2502747 subject Q7335351.
Q2502747 subject Q9052323.
Q2502747 subject Q9546190.
Q2502747 abstract "Sofosbuvir (brand name Sovaldi) is a nucleotide analog used in combination with other drugs for the treatment of hepatitis C virus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most patients to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of HCV.Sofosbuvir inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It was discovered at Pharmasset and developed by Gilead Sciences.In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4. In 2014 a combination of sofosbuvir with the viral NS5A inhibitor ledipasvir was approved. This latter combination provides high cure rates in people infected with genotype 1 (the most common subtype in the U.S., Japan, and much of Europe) without the use of interferon, irrespective of prior treatment failure or the presence of cirrhosis.The price of sofosbuvir, quoted in various media sources as $84,000 to $168,000 for a course of treatment in the U.S., £35,000 in the UK for 12 weeks has engendered considerable controversy. In September 2014, Gilead announced that it was proposing generic licensing agreements with manufacturers in 91 developing countries to produce and sell sofosbuvir, and that it would sell a name brand version of the product in India for approximately $300 per course of treatment.It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.".
Q2502747 atcPrefix "J05".
Q2502747 atcSuffix "AX15".
Q2502747 bioavailability "92.0".
Q2502747 casNumber "1190307-88-0".
Q2502747 chEBI "85083".
Q2502747 drugbank "DB08934".
Q2502747 fdaUniiCode "WJ6CA3ZU8B".
Q2502747 iupacName "Isopropyl (2S)-2-[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate".
Q2502747 pubchem "45375808".
Q2502747 thumbnail Sofosbuvir_structure.svg?width=300.
Q2502747 wikiPageExternalLink sovaldi_pi.pdf.
Q2502747 wikiPageExternalLink 28539.
Q2502747 wikiPageExternalLink www.ribavirinpregnancyregistry.com.
Q2502747 wikiPageExternalLink www.sovaldi.com.
Q2502747 wikiPageWikiLink Q1035745.
Q2502747 wikiPageWikiLink Q11000047.
Q2502747 wikiPageWikiLink Q1368197.
Q2502747 wikiPageWikiLink Q1435822.
Q2502747 wikiPageWikiLink Q15409409.
Q2502747 wikiPageWikiLink Q154869.
Q2502747 wikiPageWikiLink Q155954.
Q2502747 wikiPageWikiLink Q15787.
Q2502747 wikiPageWikiLink Q158289.
Q2502747 wikiPageWikiLink Q17050818.
Q2502747 wikiPageWikiLink Q17120609.
Q2502747 wikiPageWikiLink Q179996.
Q2502747 wikiPageWikiLink Q1954757.
Q2502747 wikiPageWikiLink Q202837.
Q2502747 wikiPageWikiLink Q204711.
Q2502747 wikiPageWikiLink Q21163344.
Q2502747 wikiPageWikiLink Q2198549.
Q2502747 wikiPageWikiLink Q22075912.
Q2502747 wikiPageWikiLink Q22921233.
Q2502747 wikiPageWikiLink Q22948482.
Q2502747 wikiPageWikiLink Q256538.
Q2502747 wikiPageWikiLink Q272631.
Q2502747 wikiPageWikiLink Q2919111.
Q2502747 wikiPageWikiLink Q2981024.
Q2502747 wikiPageWikiLink Q367700.
Q2502747 wikiPageWikiLink Q37155.
Q2502747 wikiPageWikiLink Q372713.
Q2502747 wikiPageWikiLink Q3765251.
Q2502747 wikiPageWikiLink Q410061.
Q2502747 wikiPageWikiLink Q411648.
Q2502747 wikiPageWikiLink Q421547.
Q2502747 wikiPageWikiLink Q421552.
Q2502747 wikiPageWikiLink Q421559.
Q2502747 wikiPageWikiLink Q421862.
Q2502747 wikiPageWikiLink Q422604.
Q2502747 wikiPageWikiLink Q422618.
Q2502747 wikiPageWikiLink Q422645.
Q2502747 wikiPageWikiLink Q423404.
Q2502747 wikiPageWikiLink Q4677569.
Q2502747 wikiPageWikiLink Q4743041.
Q2502747 wikiPageWikiLink Q49330.
Q2502747 wikiPageWikiLink Q509615.
Q2502747 wikiPageWikiLink Q5207712.
Q2502747 wikiPageWikiLink Q5675139.
Q2502747 wikiPageWikiLink Q6029213.
Q2502747 wikiPageWikiLink Q603741.
Q2502747 wikiPageWikiLink Q6224538.
Q2502747 wikiPageWikiLink Q663596.
Q2502747 wikiPageWikiLink Q668.
Q2502747 wikiPageWikiLink Q6814466.
Q2502747 wikiPageWikiLink Q6938881.
Q2502747 wikiPageWikiLink Q708693.
Q2502747 wikiPageWikiLink Q7132151.
Q2502747 wikiPageWikiLink Q7160835.
Q2502747 wikiPageWikiLink Q7180839.
Q2502747 wikiPageWikiLink Q7335351.
Q2502747 wikiPageWikiLink Q7517689.
Q2502747 wikiPageWikiLink Q898238.
Q2502747 wikiPageWikiLink Q9052323.
Q2502747 wikiPageWikiLink Q9546190.
Q2502747 atcPrefix "J05".
Q2502747 atcSuffix "AX15".
Q2502747 bioavailability "92.0".
Q2502747 casNumber "1190307".
Q2502747 chebi "85083".
Q2502747 drugbank "DB08934".
Q2502747 iupacName "Isopropyl -2-[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate".
Q2502747 pubchem "45375808".
Q2502747 unii "WJ6CA3ZU8B".
Q2502747 type ChemicalSubstance.
Q2502747 type Drug.
Q2502747 type ChemicalObject.
Q2502747 type Thing.
Q2502747 type Q8386.
Q2502747 comment "Sofosbuvir (brand name Sovaldi) is a nucleotide analog used in combination with other drugs for the treatment of hepatitis C virus (HCV) infection. It has been marketed since 2013. Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy.".
Q2502747 label "Sofosbuvir".
Q2502747 depiction Sofosbuvir_structure.svg.